Interleukin-17 as a drug target in human disease
(2009) In Trends in Pharmacological Sciences 30(2). p.95-103- Abstract
- Interleukin (IL)-17 (now synonymous with IL-17A) is an archetype molecule for an entire family of IL-17 cytokines. Currently believed to be produced mainly by a specific subset of CD4 cells, named Th-17 cells, IL-17 is functionally located at the interface of innate and acquired immunity. Specifically, it induces the release of chemokines and growth factors from mesenchymal cells and is now emerging as an important local orchestrator of neutrophil accumulation in several mammalian organs. Furthermore, there is growing evidence that targeting IL-17 signaling might prove useful in a variety of diseases including asthma, Crohn's disease, multiple sclerosis, psoriatric disease and rheumatoid arthritis. Here, we summarize the key aspects of the... (More)
- Interleukin (IL)-17 (now synonymous with IL-17A) is an archetype molecule for an entire family of IL-17 cytokines. Currently believed to be produced mainly by a specific subset of CD4 cells, named Th-17 cells, IL-17 is functionally located at the interface of innate and acquired immunity. Specifically, it induces the release of chemokines and growth factors from mesenchymal cells and is now emerging as an important local orchestrator of neutrophil accumulation in several mammalian organs. Furthermore, there is growing evidence that targeting IL-17 signaling might prove useful in a variety of diseases including asthma, Crohn's disease, multiple sclerosis, psoriatric disease and rheumatoid arthritis. Here, we summarize the key aspects of the biology of IL-17 in mammals and scrutinize the potential pharmacological use of targeting IL-17 in humans. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1370843
- author
- Ivanov, Stefan LU and Linden, Anders
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Trends in Pharmacological Sciences
- volume
- 30
- issue
- 2
- pages
- 95 - 103
- publisher
- Elsevier
- external identifiers
-
- wos:000263809500007
- scopus:59549083038
- pmid:19162337
- ISSN
- 0165-6147
- DOI
- 10.1016/j.tips.2008.11.004
- language
- English
- LU publication?
- yes
- id
- 4cd3f2e9-ac63-4017-ab75-e9f3b6bf9fc1 (old id 1370843)
- date added to LUP
- 2016-04-01 14:23:46
- date last changed
- 2022-01-28 00:24:15
@article{4cd3f2e9-ac63-4017-ab75-e9f3b6bf9fc1,
abstract = {{Interleukin (IL)-17 (now synonymous with IL-17A) is an archetype molecule for an entire family of IL-17 cytokines. Currently believed to be produced mainly by a specific subset of CD4 cells, named Th-17 cells, IL-17 is functionally located at the interface of innate and acquired immunity. Specifically, it induces the release of chemokines and growth factors from mesenchymal cells and is now emerging as an important local orchestrator of neutrophil accumulation in several mammalian organs. Furthermore, there is growing evidence that targeting IL-17 signaling might prove useful in a variety of diseases including asthma, Crohn's disease, multiple sclerosis, psoriatric disease and rheumatoid arthritis. Here, we summarize the key aspects of the biology of IL-17 in mammals and scrutinize the potential pharmacological use of targeting IL-17 in humans.}},
author = {{Ivanov, Stefan and Linden, Anders}},
issn = {{0165-6147}},
language = {{eng}},
number = {{2}},
pages = {{95--103}},
publisher = {{Elsevier}},
series = {{Trends in Pharmacological Sciences}},
title = {{Interleukin-17 as a drug target in human disease}},
url = {{http://dx.doi.org/10.1016/j.tips.2008.11.004}},
doi = {{10.1016/j.tips.2008.11.004}},
volume = {{30}},
year = {{2009}},
}